Methods to Facilitate Early Exploratory Testing of Novel Psychopharmacologic Agents in Humans

  • W. Z. Potter
  • R. P. Irwin
Conference paper
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 10)


The starting point for this chapter follows from three assumptions: (1) substantial numbers of patients seriously ill with psychiatric illnesses such as schizophrenia and depression show inadequate therapeutic responses to all available classes of drugs; (2) decisions to take new potential psychotropic compounds into humans are more and more based on judgments as to the likelihood of there being a reasonable market for that specific compound; and (3) pharmacologic guidance can greatly enhance the efficiency of the clinical development process both in terms of reducing wasted effort in Phase I testing and of deriving maximum information concerning the appropriate dose to test the therapeutic potential of a novel compound. With regard to this latter point, it is well known that even marketed psychotropic drugs have had very misleading dose recommendations because what is required for marketing is to establish safe doses which on average have a positive effect rather than doses which produce the maximum possible benefit.


Maximal Tolerate Dose Fusaric Acid Simultaneous Modeling Emax Model Psychopharmacologic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Colburn WA (1990) Controversy V: phase 1, first time in man studies. J Clin Pharmacol 30: 210–222PubMedGoogle Scholar
  2. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase 1 clinical trials. Cancer Treat Rev 70: 73–80Google Scholar
  3. Collins JM, Grieshaber CK, Chabner BA (1990) Pharmacologically guided phase 1 clinical trials based upon preclinical drug development. J Natl Cancer Inst 82: 1321–1326PubMedCrossRefGoogle Scholar
  4. Davis LE, Alberts DS, Plezia PM et al. (1988) Predictive model for plasma concentration versus time profiles of investigational anticancer drugs in patients. J Natl Cancer Inst 80: 815–819PubMedCrossRefGoogle Scholar
  5. Delini-Stula A (1990) Clinical trials in Europe and the development of new psychotropics as viewed by European manufacturers. Pharmacopsychiatry 23 (4): 164–70PubMedCrossRefGoogle Scholar
  6. Dreyfus JF, Cremniter D, Guelfi JD (1989) Reflections on FDA and WHO recommendations concerning clinical trials. Psychiatry Psychobiol 4: 117–122Google Scholar
  7. Elliott HL, Jones RC, Vincent J, Lawire CB, Reid JL (1984) The alpha adrenoceptor antagonist properties of idazoxan in normal subjects. Clin Pharmacol Ther 36 (2): 190–196PubMedCrossRefGoogle Scholar
  8. EORTC New Drug Development Committee (1985) EORTC guidelines for phase 1 trials with single agents in adults. Eur J Cancer Clin Oncol 21: 1005–1007CrossRefGoogle Scholar
  9. EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically-guided dose escalation in phase 1 clinical trials. Eur J Cancer Clin Oncol 23: 1083–1087CrossRefGoogle Scholar
  10. Farde L, Wiesel F-A, Halldin C, Sedvall G (1988) Central D-2 dopamine receptor occupany in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76PubMedGoogle Scholar
  11. Fuseau E, Sheiner LB (1984) Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 35 (6): 733–741PubMedCrossRefGoogle Scholar
  12. Gariano RF, Groves PM (1989) A mechanism for the involvment of colocalized neuropeptides in the actions of antipsychotic drugs. Biol Psychiatry 26 (3): 303–314PubMedCrossRefGoogle Scholar
  13. Goldsmith MA, Slavik M, Carter SK (1975) Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35: 1354–1364PubMedGoogle Scholar
  14. Goodwin FK, Sack RL (1974) Behavioral effects of a new dopamine-beta-hydroxylase inhibitor (fusaric acid) in man. J Psychiatr Res 22: 211–217CrossRefGoogle Scholar
  15. Holford NHG, Sheiner LB (1981) Understanding the dose-effect relationship: clinical applications of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429–453PubMedCrossRefGoogle Scholar
  16. Kane J, Oaks G, Honigfeld G, Singer J, Hanover NJ, Meltzer H, Cleveland MD and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45 (9): 789–796PubMedGoogle Scholar
  17. Luthra A, Borkowski KR, Carruthers SG (1991) Genetic aspects of variability in superficial vein responsiveness to norepinephrine. Clin Pharmacol Ther 49: 355–361PubMedCrossRefGoogle Scholar
  18. Osman OT, Potter WZ (1991) Potentiation of dopamine in the treatment of refractory depression. In: Amsterdam JD (ed) Refractory depression. Raven, New York, p 41 (Advances in neuropsychiatry and psychopharmacology, vol 2 )Google Scholar
  19. Osman OT, DeVane CL, Greenblatt DS, Potter WZ (1991) Pharmacokinetic and dynamic correlates of intravenous alprazolam challenge. Clin Pharmacol Ther 50: 656–662PubMedCrossRefGoogle Scholar
  20. Paalzow LK, Edlund PO (1979) Multiple receptor responses. A new concept to describe the relationship between pharmacological effects and pharmacokinetics of a drug: studies on clonidine in the rat and cat. J Pharmacokinet Biopharm 7: 495–510PubMedCrossRefGoogle Scholar
  21. Paalzow LK, Paalzow GHM, Tfelt-Hansen P (1985) Variability in bioavailability: concentration versus effect. In: Rowland M et al. (eds) Variability in drug therapy: description, estimation, and control. Raven, New York, p 167Google Scholar
  22. Peck C (1990) The randomized concentration-controlled clinical trial (CCT): an information-rich alternative to the randomized placebo-controlled clinical trial (PCT). Clin Pharmacol Ther 47 (2): 148Google Scholar
  23. Peck C, Collins J, Harter J (1990) Incorporation of pharmacokinetic and pharmacodynamic intelligence into early drug development. Clin Pharmacol Ther 47 (2): 126Google Scholar
  24. Posvar EL, Sedman AJ (1989) New drugs: first-time in man. J Clin Pharmacol 19: 961–966Google Scholar
  25. Prien RS, Potter WZ (1990) NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull 26: 409–427PubMedGoogle Scholar
  26. Salvadorini F, Galeone F, Saba P, Tognetti G, Mariani G (1980) Evaluation of S-adenosylmethionine (SAMe) effectiveness on depression. Curr Ther Res 27 (6): 908–918Google Scholar
  27. Sansone M (1978) Effects of S-adenysyl-L-methionine on the behavior of mice. In: Andreoli VM, Agnoli A, Fazio C (eds) Transmethylations and the central nervous system. Springer, Berlin Heidelberg New York, p 121Google Scholar
  28. Schwartz JB, Verotta D, Sheiner LB (1989) Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions. J Pharmacol Exp Ther 251 (3): 1032–1038PubMedGoogle Scholar
  29. Sheiner LB (1985) Modeling pharmacodynamics: parametric and nonparametric approaches. In: Rowland M et al. (eds) Variability in drug therapy: description, estimation, and control. Raven, New York, pp 139–152Google Scholar
  30. Sherer MA, Cantoni GL, Golden RN, Rudorfer MV, Potter WZ (1986) Effects of S- adenosyl-methionine on plasma norepinephrine, blood pressure, and heart rate in healthy volunteers. Psychiatry Res 17: 111–118PubMedCrossRefGoogle Scholar
  31. Shopsin B, Friedman E, Gershon S (1976) Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 33: 811–819PubMedGoogle Scholar
  32. Sjoerdsma A, Lovenberg W, Engelman K, Carpenter WT, Wyatt RJ, Gessa GL (1970) Serotonin now: clinical implications of inhibiting its synthesis with parachlorophenylalanine. J Intern Med 73: 607–629Google Scholar
  33. Taylor DP, Allen LE, Becker JA, Crane M, Hyslop DK, Riblet LA (1984) Changing concepts of the biochemical action of the anxioselective drug buspirone. Drug Dev Res 4: 95–108CrossRefGoogle Scholar
  34. Unadkat JD, Bartha F, Sheiner LB (1986) Simultaneous modeling of pharmacokinetics and pharmacodynamics with non-parametric kinetic and dynamic models. Clin Pharmacol Ther 40 (1): 86–93PubMedCrossRefGoogle Scholar
  35. Van Dyke C, Jatlow P, Ungerer J, Barash PG, Byck R (1978) Oral cocaine: plasma concentrations and central effects. Science 200: 211–213PubMedCrossRefGoogle Scholar
  36. Verotta D, Sheiner LB (1987) Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm. Comput Appl Biosci 3 (4): 345–349PubMedGoogle Scholar
  37. Wagner JG (1968) Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20: 171–201CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • W. Z. Potter
    • 1
  • R. P. Irwin
    • 2
  1. 1.Section on Clinical Pharmacology, Experimental Therapeutics BranchNational Institute of Mental HealthBethesdaUSA
  2. 2.National Institute of General Medical Sciences and Clinical Neuroscience BranchNational Institute of Mental HealthBethesdaUSA

Personalised recommendations